HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) Subsidiary Pentavere Wins Prestigious Prix Galien USA 2024 Award

4 min read | November 12, 2024 05:49 AM EST | By Team Kalkine Media

Highlights:

  • Pentavere’s DARWEN™ AI platform wins Prix Galien USA 2024 award in Digital Health & Medical Technology.
  • HEALWELL’s subsidiary recognized for making healthcare more accessible and personalized for patients.
  • Award marks Pentavere’s first win after three prior nominations, solidifying its role as a leader in AI healthcare innovation.

HEALWELL AI Inc. (TSX:AIDX) (OTCQX:HWAIF) has announced that its subsidiary, Pentavere Research Group ("Pentavere"), has been awarded the prestigious Prix Galien USA 2024 prize in the Best Startup category for Digital Health & Medical Technology. This accolade highlights Pentavere's DARWEN™ AI platform, which has proven to be a transformative force in making healthcare more accessible and personalized. The award marks a significant milestone for Pentavere, as it was selected from 43 nominees, and is the company’s first win after three previous nominations in the Prix Galien awards.

The Prix Galien USA, one of the most esteemed awards in the global health innovation industry, recognizes outstanding achievements in biomedical and medical technology that improve patient care and the human condition. The award was presented on November 7, 2024, during a ceremony at the American Museum of Natural History in New York. Former U.S. President Bill Clinton has referred to the Prix Galien as "equivalent to the Nobel Prize" in life sciences, underscoring its prestige and the significance of the recognition.

Aaron Leibtag, CEO and Co-Founder of Pentavere, expressed his pride in receiving the honor: "We are honored to receive this prestigious award from The Galien Foundation in recognition of our best-in-class DARWEN™ AI platform for the impact it is having for providers and patients." Leibtag further emphasized Pentavere's vision: "At Pentavere, we envision that using AI to fully understand the entire patient journey at scale could be as transformative as decoding the human genome."

Pentavere’s DARWEN™ AI platform is designed to revolutionize the way healthcare providers and patients interact by leveraging data science and artificial intelligence. The platform uses sophisticated algorithms to analyze vast amounts of healthcare data, offering valuable insights that allow for more personalized treatment and better patient outcomes. By understanding the entire patient journey, from early diagnosis to treatment and ongoing care, DARWEN™ helps healthcare providers deliver precision medicine and facilitates more efficient, cost-effective care.

This achievement also aligns with HEALWELL’s broader mission to utilize AI and data science to drive preventative care and improve the accessibility and quality of healthcare. Pentavere’s success with DARWEN™ is a testament to the company’s commitment to harnessing AI to solve some of the most pressing challenges in the healthcare industry.

The Prix Galien Award is a global benchmark for excellence in life sciences, and its recognition is highly sought after in the industry. The awards have been presented annually since 2007, and recipients are chosen by a distinguished panel of global thought leaders and experts in biomedical and medical technology. The recognition not only validates the impact of Pentavere’s work but also highlights the growing importance of AI in reshaping healthcare delivery.

Pentavere’s recognition in the Best Startup category for Digital Health & Medical Technology is a significant achievement, and it underscores the company’s role as a leader in AI-powered healthcare innovation. The award also serves as a catalyst for further development and commercialization of Pentavere's cutting-edge AI solutions.

This win is just the beginning for Pentavere and HEALWELL, which continue to expand their reach and influence within the digital health and AI sectors. With its growing portfolio of AI solutions and a strong commitment to improving patient care, Pentavere is poised to continue making significant strides in the healthcare space. The Prix Galien USA 2024 award serves as a recognition of the company’s impact and a stepping stone toward even greater achievements.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.